Evidence mapPaperPMID 42535010Full record

ArticleFrontiers in psychology2026

Effects of an open-label placebo on divergent thinking performance.

Stopper Marlies, Albert Wabnegger, Janika Saretzki, Corina Scheer, Anne Schienle

Abstract read
In one paragraph

Article in Frontiers in psychology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Stopper MarliesSection of Clinical Psychology, Department of Psychology, University of Graz, Graz, Austria.
Albert WabneggerSection of Clinical Psychology, Department of Psychology, University of Graz, Graz, Austria.
Janika SaretzkiCreative Cognition Lab, Department of Psychology, University of Graz, Graz, Austria.
Corina ScheerSection of Clinical Psychology, Department of Psychology, University of Graz, Graz, Austria.
Anne SchienleSection of Clinical Psychology, Department of Psychology, University of Graz, Graz, Austria.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Placebos deceptively labeled as "creativity enhancers" have been shown to improve divergent thinking (DT) performance. This study examined whether nondeceptive placebos administered with full transparency, which are also known as open-label placebos (OLPs) can produce comparable effects when framed as enhancing either cognitive or affective processes. Methods: Participants were randomly assigned to one of three groups that completed the Alternative Uses Task (AUT) twice within a single testing session. After the first AUT (baseline), two groups received a placebo pill, which was introduced either as a "creativity enhancer" or a "mood enhancer", whereas the third group received no treatment. Objective outcomes included DT performance (fluency, originality, and flexibility); subjective measures comprised ratings of mood, attention, performance perception, and expected/perceived placebo efficacy. Results: The study included 105 participants (mean age: 29.6 years, SD = 9.63, 62% female). Placebo administration improved subjective outcomes but did not affect DT performance (all Conclusion: These placebo effects were limited to subjective states and were comparable across the creativity- and mood-enhancement suggestion conditions, highlighting the need for future research to further investigate the role of content-specific suggestions in placebo responsiveness.

Indexed as

alternative usescreativitydivergent thinkingmoodopen-label/nondeceptive placebosperformanceplacebos

Identifiers

PMID42535010
PMCPMC13422469

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.